| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
17754423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Aducanumab
CAS:1384260-65-4
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Nanjing Peptide Biotech Ltd.
|
| Tel: |
025-025-58361106-805-805 13082558573 |
| Email: |
liugang@njpeptide.com |
| Products Intro: |
Product Name:Aducanumab
CAS:1384260-65-4
Purity:90%HPLC,95%HPLC,98%HPLC Package:5mg,20mg,100mg,250mg,500mg,1g
|
|
| | Aducanumab Basic information |
| Product Name: | Aducanumab | | Synonyms: | Aducanumab;AducanumabQ: What is
Aducanumab Q: What is the CAS Number of
Aducanumab;Research Grade Aducanumab(DHC12504);Aducanumab (anti-APP);BIIB037 | | CAS: | 1384260-65-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Aducanumab Structure]() |
| | Aducanumab Chemical Properties |
| storage temp. | Store at -80°C, Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws | | form | Liquid | | color | Colorless to light yellow |
| | Aducanumab Usage And Synthesis |
| Enzyme inhibitor | This high-affinity, fully human IgG1 monoclonal antibody (MW = 149.5 kDa; CAS 1384260-65-4), also known by the developmental code name BIIB037, selectively targets aggregated forms of b-amyloid protein (EC50 = 0.1 nM), while showing weak binding to Ab monomer. In the brains of transgenic mice, aducanumab preferentially binds to parenchymal Aβ over vascular Aβ deposits, consistent with the lack of effect on vascular Aβ following chronic dosing. Aducanumab dose-dependently reduces amyloid deposition in six cortical regions of the brain. chAducanumab, a murine IgG2a/κ chimeric analogue, dose-dependently reduces Aβ measured in brain homogenates by up to 50% relative to the vehicle control in the diethylamine fraction that extracted soluble monomeric and oligomeric forms of Aβ40 and Aβ42, and in the guanidine hydrochloride fraction that extracted insoluble Aβ fibrils. The clearance of Aβ deposits was accompanied by enhanced recruitment of microglia. Together with the reduced potency of the aglycosylated form of chaducanumab and the ex vivo phagocytosis data, such findings suggest that FcγR-mediated microglial recruitment and phagocytosis played an important role in Aβ clearance in these models. Activated microglia appeared to encapsulate the remaining central dense core of plaques in treated animals, possibly isolating them from the surrounding neurophil. |
| | Aducanumab Preparation Products And Raw materials |
|